EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 589 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Droplet Transmission vs. Airborne… What’s the difference? August 10, 2020 R2-ISS: an Improved and Simple Prognostic Staging System Allows Better Stratification... June 1, 2022 Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... July 2, 2021 FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... February 7, 2023 Load more HOT NEWS Contraception and cancer – a look behind the headlines FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type...
